AirSculpt Technologies, Inc. Files 10-K/A Restatement: Key Points for Investors

Overview

AirSculpt Technologies, Inc. (“Company”) has filed Amendment No. 1 to its Annual Report on Form 10-K for the year ended December 31, 2025. This amendment was submitted to correct errors in the presentation of certain non-GAAP financial measures originally included in Part II, Item 7 (“Management’s Discussion and Analysis of Financial Condition and Results of Operations” or “MD&A”). These corrections do not affect the Company’s consolidated financial statements prepared in accordance with GAAP, nor the related audit opinion, but do impact how the Company’s Adjusted EBITDA, Adjusted EBITDA Margin, and Adjusted Net (Loss)/Income were previously reported.

Key Points of the Report

• Restatement of Non-GAAP Financial Measures:
  • A one-time non-cash adjustment related to the closure of the London facility was inaccurately included in the calculation of Adjusted EBITDA, Adjusted EBITDA Margin, and Adjusted Net (Loss)/Income.
  • This resulted in an overstatement of Adjusted EBITDA and Adjusted Net (Loss)/Income by approximately \$2.6 million, and an overstatement of Adjusted EBITDA Margin by about 1.7% for the year ended December 31, 2025.
  • Additionally, an error related to the tax effect of adjustments within Adjusted Net (Loss)/Income resulted in an overstatement by \$2.7 million, with a net overstatement of \$0.1 million for the year ended December 31, 2025.
• Impact on Shareholders and Investors:
  • The errors were material to the presentation of non-GAAP financial metrics, which are often used by investors and analysts to assess operational performance and valuation.
  • While GAAP financials remain unaffected, the correction may alter investor perception regarding the Company’s operational profitability and growth, potentially impacting share price.
  • There are no new material weaknesses in internal control over financial reporting identified as a result of this amendment.
  • Shareholders should note that the amendment does not change any other information, items, or disclosures from the original filing, and all information is as of the original filing date (March 31, 2026).
• Business Performance Highlights:
  • AirSculpt’s operating model is described as highly scalable and capital efficient, requiring minimal maintenance capital expenditures and working capital.
  • For the year ended December 31, 2025, the Company generated approximately \$152 million in revenue, down from \$180 million in 2024, representing a 15.8% decline.
  • The Company is implementing cost-saving initiatives and revenue growth strategies to address the revenue declines experienced in 2024 and 2025.
  • Growth strategies include increasing procedure prices, optimizing marketing investment, expanding consumer financing options, and introducing new product lines.
• Risks and Uncertainties:
  • The Company faces risks related to macroeconomic trends, including inflation and rising interest rates, which may adversely impact financial condition and results.
  • Other risks include increased competition, potential regulatory changes, disruptions from natural disasters, geopolitical instability, and business disruptions from government shutdowns.
  • There is a risk that cost-saving initiatives and revenue growth strategies may not deliver the anticipated benefits.
  • The Company’s variable rate debt exposes it to risks associated with rising interest rates.
  • Use of social media and messaging services also presents reputational and regulatory risks.
• Shareholder Information:
  • As of March 30, 2026, the Company had 70,545,681 shares of common stock outstanding.
  • The aggregate market value of common shares held by non-affiliates was \$79.8 million at the end of the most recent second fiscal quarter.
  • The Company is an “emerging growth company” and a “smaller reporting company,” which affects disclosure requirements.
  • No cash dividends are planned for the foreseeable future.
• Regulatory and Legal Matters:
  • The Company operates in a highly regulated healthcare environment, with increasing scrutiny from state regulators, particularly in states like California, Massachusetts, and New York.
  • Regulatory changes may impact the Company’s structure and profitability.
  • The Company believes it is materially compliant with applicable laws but acknowledges some laws are subject to limited or evolving interpretations.
• Cautionary Note on Forward-Looking Statements:
  • The report contains forward-looking statements about future financial performance and growth strategies, which are subject to significant risks and uncertainties.
  • Investors should not place undue reliance on these statements, as actual results may differ materially.

Potential Price-Sensitive Developments

• Restatement of Non-GAAP Financials:
  • The correction of overstated non-GAAP measures could impact analyst models, investor sentiment, and valuation assessments, especially for those who rely on these metrics for investment decisions.
  • Investors should adjust their expectations regarding Adjusted EBITDA and Adjusted Net Income for FY2025, which were previously overstated.
• Revenue Decline and Cost Initiatives:
  • The reported 15.8% revenue drop may prompt questions about the Company’s growth trajectory and competitive position.
  • Effectiveness of cost-savings and growth strategies will be critical to future performance and investor confidence.
• Regulatory Scrutiny:
  • Increasing state regulatory scrutiny could pose risks to the Company’s operational structure and profitability.
• Risks to Debt and Financing:
  • Exposure to rising interest rates and restrictive covenants in debt instruments may affect future cash flows, capital raising, and operational flexibility.

Conclusion

The restatement of non-GAAP financial measures by AirSculpt Technologies, Inc. is a significant event for investors, as it alters previously reported operational profitability and may influence share price and valuation. All other GAAP financials remain unchanged, but investors should note the risks associated with business execution, regulatory changes, and macroeconomic trends. The Company’s future performance will depend on the successful implementation of its cost-saving and growth strategies.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. All forward-looking statements are subject to risks and uncertainties. Investors should conduct their own due diligence and consult with a professional advisor before making investment decisions. The information is based on the Company’s SEC filings as of the original report date and may not reflect subsequent developments.

View Airsculpt Technologies, Inc. Historical chart here